Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase NA 19Phase 3 15Phase 1/2 5Phase 1 5Phase 2/3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × Pathologic Complete Response × Clear all
NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Active not recruiting
17 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡